AbbVie Plans $10.1B Acquisition of ImmunoGen to Speed Entry Into Ovarian Cancer Market

November 30, 2023 |

AbbVie and ImmunoGen today announced an agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx) an antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer, accelerating AbbVie’s presence in the solid tumor space.
Source: Drug Industry Daily